AKT signaling
RAC-alpha serine/threonine kinases (AKTs) are crucial
mediators of various cellular process, such as apoptosis, regulation of cell cycle,
protein synthesis and regulation of metabolism. The activity of
AKT is modulated by various proteins, including
Phosphatidylinositol-3-kinase (PI3K),
Phosphoinositide-dependent kinase 1 (PDK), phosphotases
PTEN, PP2A, and heat-shock
protein (Hsp90).
PI3K converts phosphatidylinositol 4,5-biphosphate
(PI(4,5)P2) to phosphatidylinositol
3,4,5-triphosphate (PI(3,4,5)P3), which is
secondary messenger involved the in regulation of various process [1].
PI(3,4,5)P3 associates with the inner lipid
bilayer of the plasma membrane and promotesthe recruitment of proteins with pleckstrin
homology (PH) domains such as AKT and
PDK. Upon binding to the membrane
AKT and PDK became active.
Notably, translocation of AKT to the plasma membrane also
facilitates its phosphorylation by PDK
[2].
AKT activity can be inhibited indirectly though the t
phosphatase PTEN that cleaves the 3' phosphate from
PI(3,4,5)P3 to generate
PI(4,5)P2. PTEN
therefore, acts to decrease levels of PI(3,4,5)P3
causing an antagonistic effect of AKT-inducedcell survival
[3].
The phosphatase PP2A dephosphorylates and inhibits
AKT directly and this is counteracted by
Hsp90. Hsp90 forms a complex with
AKT and prevents PP2A-mediated
dephosphorylation. Hsp90 plays an important role in
maintaining AKT kinase activity [4].
Activated AKT prevents cells from undergoing apoptosis by
inhibiting proapoptotic proteins BCL2-associated agonist of cell death
(BAD) and Caspase-9 [5]. AKT induces phosphorylation of BAD,
preventing BAD from
binding with anti-apoptotic factor BCL2-like 1
(BCL-X) therby reducing antiapoptotic events [6].
AKT can interfere with cell death via a member of the
forkhead family of transcription factors (e.g., Forkhead box O3
(FOXO3A), which is a direct target for phosphorylation by
AKT). FOXO3A has been
implicated in the expression of the FAS ligand (FasL) and
the Bcl-2 interacting mediator of cell death (Bim), which
can induce cell death. Upon phosphorylation by AKT,
FOXO3A is retained in the cytosol preventing transcriptional
regulation and expression of FasL and
Bim in the nuclease, allowing the cell survival [7].
AKT also regulates the activity of other transcription
factors, such as nuclear factor-kappaB (NF-kB), Tumor
protein p53 (p53), c-Myc. AKT
phosphorilates and activates I-kB kinase (IKK), that
regulate the activity of the NF-kB transcription factor.
When bound to its cytosolic inhibitor I-kB,
NF-kB is inactive. Upon phosphorylation of
I-kB by IKK, the inhibitor is
degraded, allowing NF-kB to move to the nucleus and activate
the transcription of antiapoptotic proteins [8].
AKT phosphorylates ubiquitin-protein ligase E3 Mdm2 p53
binding protein homolog (MDM2) that results in its
translocation into the nucleus where it binds to transcription factor
p53. p53 mediates apoptosis
through transactivation of apoptotic activator BAX [9]. MDM2 interacts with the p53,
inhibits its transcriptional activity and targets it for degradation by
the proteasome [10].
AKT affects the cell cycle progression by regulating the
Cyclin D function. This is accomplished by phosphorylation
of Cyclin-dependent kinase inhibitor 1A (p21/WAF1) by
AKT. This result to cytoplasmic localization of
p21/WAF1, thereby preventing its function in the nucleus. In
the nucleous, the protein p21/WAF1 interacts with and
inhibits the essential DNA replication factor, proliferating-cell nuclear antigen
(PCNA). p21/WAF1
and PCNA forms complex with
Cyclin D [11].
Another target for AKT is
Glycogen synthase kinase 3 (GSK3), which
negativly regulates glycogen synthesis and cell cycle progression via inhibitory
phosphorylation of glycogen synthase and transcription factors c-Myc
and Cyclin D, respectively.
Additionally, FOXO3A has been implicated in expression of
the Cyclin-dependent kinase inhibitor 1B (P27KIP1), which
binds with and inhibits Cyclin D [12].
The activation of AKT results in the stimulation of
protein synthesis via activation of Ribosomal protein S6 kinase
(p70S6K). The activation of
p70S6K by AKT occurs via direct
and indirect mechanisms. The indirect process is mediated by FKBP-rapamycin associated
protein (FRAP1). In absence of
AKT-mediated phosphorylation,
Tuberin via the small GTPase
Rheb inhibits FRAP1, allowing
the activation of P70S6K the
leads to multiple phosphorylation events of 40S ribosomal protein S6
(RPS6) to trigger protein synthesis [13].
References:
- Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD
Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer.
Annual review of cell and developmental biology 2001;17:615-75
- Brader S, Eccles SA
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.
Tumori 2004 Jan-Feb;90(1):2-8
- Downward J
PI 3-kinase, Akt and cell survival.
Seminars in cell & developmental biology 2004 Apr;15(2):177-82
- Sato S, Fujita N, Tsuruo T
Modulation of Akt kinase activity by binding to Hsp90.
Proceedings of the National Academy of Sciences of the United States of America 2000 Sep 26;97(20):10832-7
- Tsugawa K, Jones MK, Sugimachi K, Sarfeh IJ, Tarnawski AS
Biological role of phosphatase PTEN in cancer and tissue injury healing.
Frontiers in bioscience : a journal and virtual library 2002 May 1;7:e245-51
- Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, Dikkes P, Korsmeyer SJ, Greenberg ME
Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis.
Developmental cell 2002 Nov;3(5):631-43
- Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA
A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells.
Cancer cell 2003 Dec;4(6):463-76
- Agarwal A, Das K, Lerner N, Sathe S, Cicek M, Casey G, Sizemore N
The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin.
Oncogene 2005 Feb 3;24(6):1021-31
- Shen Y, White E
p53-dependent apoptosis pathways.
Advances in cancer research 2001;82:55-84
- Gottlieb TM, Leal JF, Seger R, Taya Y, Oren M
Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis.
Oncogene 2002 Feb 14;21(8):1299-303
- Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC
Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells.
Nature cell biology 2001 Mar;3(3):245-52
- Liang J, Slingerland JM
Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.
Cell cycle (Georgetown, Tex.) 2003 Jul-Aug;2(4):339-45
- Panwalkar A, Verstovsek S, Giles FJ
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Cancer 2004 Feb 15;100(4):657-66